Q32 Bio CEO sells shares to cover taxes

Q32 Bio Inc. CEO and director Jodie Pope Morrison reported an open-market sale of 9,896 shares of common stock on February 25, 2026 at a weighted average price of $4.5144 per share.

Accepted by SEC EDGAR 02/27/2026 - 07:00 PM EST Learn about SEC filing dates

Rhea-AI Filing Summary

Q32 Bio Inc. CEO and director Jodie Pope Morrison reported an open-market sale of 9,896 shares of common stock on February 25, 2026 at a weighted average price of $4.5144 per share. According to the disclosure, these shares were required to be sold to cover tax withholding obligations related to the vesting of restricted stock units, and the sales were automatic and not at her discretion. The trades occurred in multiple transactions at prices ranging from $4.35 to $4.69 per share. After these sales, she directly owned 89,104 Q32 Bio shares.

Insider Trade Summary

Net Seller: 9,896 shares

Net Sell 1 txn

Insider Morrison Jodie Pope

Role CEO

Sold 9,896 shs ($45K)

Share of Position Sold 10.0%

Type	Security	Shares	Price	Value
Sale	Common Stock	9,896	$4.5144	$45K

Holdings After Transaction: Common Stock — 89,104 shares (Direct)

Holdings Before and After: Common Stock, 99,000 to 89,104 shares (Direct)

Other Insiders: 2 other insiders reported open-market sales of this stock in the 30 days up to this filing.

Footnotes (2)

1. F1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.
2. F2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Q32 Bio (QTTB) disclose on this Form 4?

Q32 Bio reported that CEO and director Jodie Pope Morrison sold 9,896 shares of common stock. The filing classifies this as an open-market sale on February 25, 2026, related to tax withholding from restricted stock unit vesting.

How many Q32 Bio (QTTB) shares did the CEO sell and at what price?

The CEO sold 9,896 shares of Q32 Bio common stock at a weighted average price of $4.5144 per share. The shares were sold in multiple trades, with individual prices ranging from $4.35 to $4.69 per share.

Why were Q32 Bio (QTTB) shares sold by the CEO in this filing?

The shares were sold to cover tax withholding obligations arising from the vesting of restricted stock units. The Form 4 notes these sales were automatic and not made at the discretion of CEO Jodie Pope Morrison.

Were the Q32 Bio (QTTB) CEO’s share sales discretionary trades?

No, the filing states the sales were automatic to satisfy tax withholding obligations tied to restricted stock unit vesting. It specifically notes the transactions were not carried out at the discretion of the reporting person.

How many Q32 Bio (QTTB) shares does the CEO hold after the reported sale?

Following the sale of 9,896 shares, CEO Jodie Pope Morrison directly holds 89,104 shares of Q32 Bio common stock. This post-transaction ownership figure is disclosed in the Form 4 as the total shares following the transaction.

What trading range is disclosed for the Q32 Bio (QTTB) CEO’s share sale?

The filing notes the weighted average sale price was $4.5144 per share, with individual trades executed between $4.35 and $4.69. The CEO undertakes to provide detailed trade breakdowns upon request to specified parties.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Morrison Jodie Pope

(Last) (First) (Middle)

Q32 BIO INC.

830 WINTER STREET

(Street)

WALTHAM MA 02451

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Q32 Bio Inc. [ QTTB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CEO

3. Date of Earliest Transaction (Month/Day/Year)
02/25/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/25/2026		S(1)		9,896	D	$4.5144(2)	89,104	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units. These sales were automatic and not in the discretion of the Reporting Person.

2. The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $4.35 to $4.69. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, on request, full information regarding the number of shares sold at each separate price within the range set forth above.

	/s/ Eric Bell, Attorney-in-Fact	02/27/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.